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Human infections with viruses of the genus Flavivirus, including
dengue virus (DENV) and Zika virus (ZIKV), are of increasing
global importance. Owing to antibody-dependent enhancement
(ADE), secondary infection with one Flavivirus following
primary infection with another Flavivirus can result in a
significantly larger peak viral load with a much higher risk of
severe disease. Although several mathematical models have
been developed to quantify the virus dynamics in the primary
and secondary infections of DENV, little progress has been
made regarding secondary infection of DENV after a primary
infection of ZIKV, or DENV-ZIKV co-infection. Here, we
address this critical gap by developing compartmental models
of virus dynamics. We first fitted the models to published data
on dengue viral loads of the primary and secondary infections
with the observation that the primary infection reaches its peak
much more gradually than the secondary infection. We then
quantitatively show that ADE is the key factor determining a
sharp increase/decrease of viral load near the peak time in the
secondary infection. In comparison, our simulations of DENV




































show that ADE has very limited influence on the peak DENV viral load. This indicates pre-existing
immunity to ZIKV is the determinant of a high level of ADE effect. Our numerical simulations
show that (i) in the absence of ADE effect, a subsequent co-infection is beneficial to the second
virus; and (ii) if ADE is feasible, then a subsequent co-infection can induce greater damage to the
host with a higher peak viral load and a much earlier peak time for the second virus, and for the
second peak for the first virus.ing.org/journal/rsos
R.Soc.Open
Sci.7:1917491. Introduction
Dengue virus (DENV), transmitted by Aedes aegypti and Aedes albopictus mosquitoes, infects 50–100
million people yearly, including 500 000 dengue hemorrhagic fever (DHF) cases and 22 000 deaths
[1,2]. Zika virus (ZIKV), also a member of the Flaviviridae family, genus Flavivirus, is transmitted by
the same mosquitoes. Human infection with ZIKV is usually accompanied by relatively mild
symptoms, but can be associated with more severe effects such as Guillain–Barré syndrome and fetal
microcephaly [3,4], prompting global concern.
Infection with any of the four closely related dengue serotypes (DENV 1, DENV 2, DENV 3 and
DENV 4) induces protective immunity to that serotype, but confers no long-term protection against
infection by other serotypes. Experimental evidence [5] has indicated that infection with one dengue
serotype provides a temporal window of cross-protection towards other dengue serotypes, and the
study of Reich et al. [6] provided the quantitative measure of short-term cross-protection among
the different dengue serotypes.
By contrast, several studies [7–9] have reported that prior ZIKV infection can induce significant low
levels or no cross-neutralizing effect of secondary infection with any dengue serotype, suggesting that
ZIKV lies outside the DENV serocomplex [8]. In [10], Dejnirattisai et al. concluded that most antibodies
which reacted to the DENV envelope protein also reacted to ZIKV. More specifically, DENV-specific
antibodies can bind ZIKV but are unable to neutralize the virus, and consequently facilitate ZIKV
infection with a high level of Zika viral loads in the host. This phenomenon is referred as antibody-
dependent enhancement (ADE) [10–13]. Correspondingly, Valiant et al. [9] showed that ZIKV-exposed
macaques present a high level of DENV cross-reactive binding antibody with low DENV neutralizing
activity, indicating the occurrence of enhancement of the dengue infection. In addition, George et al. [14]
showed that prior exposure to ZIKV significantly enhances DENV viremia. It is accepted that ADE has
been well-documented among different dengue serotypes [15–17]. In particular, driven by ADE, a
secondary infection of dengue with a different serotype from the first infection is much more severe
than the primary infection, and has been linked with the increase in DHF [18,19].
On the one hand, several mathematical epidemiological modelling studies [20–23] have examined the
epidemiological impact of ADE on the prevalence and persistence of different dengue serotypes at the
population level. In the studies [20,21], the authors showed that ADE can induce large-amplitude
oscillations and other complex long-term behaviours in the incidence. By extending the model in [21],
Billings et al. were able to conduct some computational analyses to suggest optimal vaccination
strategies [23]. Also, a modelling study reported that a dengue vaccine used in a population may
increase ZIKV outbreaks under certain conditions owing to ADE [24]; however, the work [25] also
showed that an appropriately designed and optimized dengue vaccination programme can not only
help control the dengue spread but also reduce ZIKV infections. On the other hand, several within-
host mathematical models were proposed and used to quantitatively analyse [26–28] or theoretically
investigate [29–31] the impact of ADE on the viral dynamics of primary and secondary infection of
different dengue serotypes. Note that, both studies [28,31] highlighted the important role of antibody
in controlling the viral replication. However, to the best of our knowledge, there is no mathematical
study evaluating the impact of ADE on the viral dynamics in the secondary infection or the co-
infection of DENV and ZIKV. This study aims to quantitatively address these issues.
The rest of the paper is organized as follows. In the coming section, we propose models describing
virus dynamics for a primary infection of DENV; for a secondary infection of DENV with a previous
infection of ZIKV; and for co-infection of DENV and ZIKV. In §3, we calibrate our models by fitting
them to some data of dengue viral loads. In §4, through a sensitivity analysis (SA) and some
numerical simulations, we discuss the impact of ADE on the peak value and time of dengue viral
loads. Finally, in §5, we summarize the main results and elaborate these modelling analyses in the







































2.1. Primary infection of single virus
The within host viral dynamics of Flaviviruses, including dengue [26–28] and Zika [32,33], has been
studied intensively. The viral dynamics with antibody mediated immune response is described by the
following ordinary differential equation system:
dT(t)
dt














where T is the target cell, V the free virus, I the infected cells and A the antibody specific to the virus
V. Here, we assume that the target cells are recruited at a constant rate Λ and die at the rate μ, free
viruses infect the target cells through a mass-action progress at a rate β, δ denotes the death rate of
the infected cell, ω is the production rate of the free virus, and c is the clearance rate of free viruses.
The antibody A can be stimulated by the free virus with a production rate a while it declines at a rate
of σ. The antibody A can neutralize the free virus at the rate of b.2.2. Secondary infection with antibody-dependent enhancement
We focus on the case of a secondary DENV infection with a primary ZIKV infection. Without loss of
generality, we assume that the individual has recovered from ZIKV, hence, free ZIKV has been
cleared. After the secondary infection with DENV, antibodies specific to it will be activated.
Meanwhile, owing to the cross-immune response between DENV and ZIKV, antibodies specific to
ZIKV will be stimulated by the free DENV as well. As mentioned in the introduction, ZIKV-specific
antibodies can bind DENV, and consequently, contribute to the replication of DENV (i.e ADE effect)
[9]. On the other hand, as demonstrated in the experimental study [9], the delayed cross-neutralization
of ZIKV-specific antibody to DENV occurs in the secondary DENV infection. Hence, it is reasonable
to assume that at a high level of ZIKV-specific antibody, it can help in clearing the DENV (antibody-
dependent neutralization (ADN)). As a conclusion, we assume that the ZIKV-specific antibody can
present ADE to DENV only when its concentration reaches a certain level. Once the concentration of
ZIKV-specific antibody exceeds a threshold level, it can help in neutralizing DENV (ADN). Therefore,
based on the above assumptions, we propose the follow model describing the within-host dynamics
of the secondary DENV infection with a primary infection of ZIKV:
dT(t)
dt

















where T is the target cells, Id the cells infected by DENV, Vd the free DENV, Ad the DENV-specific
antibody and Az the ZIKV-specific antibody. A schematic diagram of the secondary infection
of DENV with a primary infection of ZIKV is shown in figure 1a. Here, κ is the production rate of
ZIKV-specific antibody Az owing to its cross-immune response to DENV and σsz denotes the clearance






































































Figure 1. Schematic diagrams. (a) Schematic diagram for the secondary infection of DENV with a primary infection of ZIKV.
(b) Schematic diagram of the co-infection of DENV and ZIKV.
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rate of free DENV owing to the cross-reactive response of ZIKV-specific antibody to DENV. S is a
switching function of Az with the following form [29]:
S(Az) ¼ tanh (a1(Az  Amax))1þ ea2(AzAmin) : (2:3)
It is used here to describe the continuous switching between the ADE and the ADN of ZIKV-specific
antibody to DENV. In this study, we fixed α1 = α2 = 0.05 so that as Az increases, S(Az) first increases when
Az is less than Amin, reaches and remains at the value of 1 for a certain interval of Az, then decreases to 0
when Az touches Amax, and finally decrease to −1, as shown in figure 2. Correspondingly, θd S denotes
the replication rate of free DENV owing to the ADE of ZIKV-specific antibody to DENV when Az∈ (0,
Amax), while it represents the clearance rate of free DENV owing to the cross-neutralization of ZIKV-
specific antibody to DENV when Az >Amax. Thus, Amax is the threshold level of ZIKV-specific antibody
for presenting ADE or ADN to DENV. Note that, for the very low concentration of the heterologous
antibodies, the probability of its interaction with virus should be low or zero. Amin can be seen as a
modification parameter for the low concentration of ZIKV-specific antibody presenting low level of
ADE. The infection dynamics of DENV and the DENV-specific immune response are treated to be
similar to the primary DENV infection, hence the definitions of other parameters are similar to those in
model (2.1), which are listed in table 1.
Table 1. Parameters definitions and values.
definitions mean (std) references
parameters
Λ the rate at which the target cells are created 57865 (4304) estimated by
model (2.1)
μ the death rate of the target cells 0.14 [28]
δ the death rate of infected cells 0.14 [28]
βd the infection rate of DENV 2.34 × 10
−9 (1.29 × 10−10) estimated by
model (2.1)
βz the infection rate of ZIKV βd assumed
ωd production rate of DENV 1 × 10
4 [28]
ωz production rate of ZIKV 1 × 10
4 [28]
cd clearance rate of DENV 10 [32,34]
cz clearance rate of ZIKV 10 [32,34]
σd decay rate of DENV-specific antibody Ad 3.99 × 10
−4 (2.87 × 10−5) estimated
by model (2.1)
σz decay rate of ZIKV-specific antibody Az σd assumed
ad production rate of DENV-specific antibody Ad 5.56 × 10
−5 (1.4 × 10−6) estimated by
model (2.1)
az production rate of ZIKV-specific antibody Az ad assumed
bd neutralization rate of DENV-specific antibody to
DENV
0.95 (0.1) estimated by
model (2.1)
bz neutralization rate of ZIKV-specific antibody to
ZIKV
bd assumed
θd maximum changing rate of DENV owing to
cross-reactive response of Az to it
0.343 (0.078) estimated by
model (2.2)
θz maximum changing rate of ZIKV owing to cross-
reactive response of Ad to it
θd assumed
κ production rate of ZIKV-specific antibody owing
to cross-immune response
7.86 × 10−5 (1.01 × 10−5) estimated by
model (2.2)
σsz clearance rate of ZIKV-specific antibody in the
second infection of DENV
5.5 × 10−4 (1.9 × 10−5) estimated by
model (2.2)
Amin parameter for low ZIKV-specific antibody
presenting low level of ADE
35.3 (2.83) estimated by
model (2.2)
Amax threshold value between ADE and ADN of
ZIKV-specific antibody to DENV
1580.2 (143.57) estimated by
model (2.2)
initial values
T(0) initial DENV-infected cells 1.98 × 106 (1.14 × 105) estimated by
model (2.1)
Id(0) initial DENV-infected cells 0 assumed
Vd(0) initial density of DENV 1 assumed
Ad(0) initial DENV-specifical antibody 0.988 (0.056) estimated by
model (2.1)
Az(0) initial ZIKV-specifical antibody
(for model (2.2) only)












































































2.3. Co-infection of dengue virus and Zika virus with antibody-dependent enhancement
Owing to the short-term cross-protection of different dengue serotypes, it is considered to be rare that
one individual is infected with two or more different dengue serotypes simultaneously. However,
differing from the relationship among different DENV serotypes, the no or low level cross-protection
between DENV and ZIKV indicates the possibility of the co-infection of these two viruses [9,35,36].
The virus dynamics of the co-infection of DENV and ZIKV can be described as follows:
dT(t)
dt









¼ vdId(t) cdVd(t) bdAd(t)Vd(t)þ udS(Az)Az(t)Vd(t),
dVz(t)
dt











where T, Vd, Vz, Id, Iz, Ad, Az denote the target cells, free DENV, free ZIKV, DENV-infected cells, ZIKV-
infected cells, DENV-specific antibody and ZIKV-specific antibody, respectively. A schematic diagram of
the co-infection of DENV and ZIKV is shown in figure 1b. Here, we take the DENV-specific immune
response and the ZIKV-specific immune response to be similar to the primary infection, as the
definitions of all the parameters are listed in table 1. Therefore, the production rate and the clearance
rate of the ZIKV-specific antibody Az are different from those in the secondary infection. In addition,
we take into consideration the cross-binding effect of the antibodies to the viruses. Here, similarly to
the secondary infection, we use the parameter θd and the switching function S(Az) to describe the
ADE effect or ADN effect of ZIKV-specific antibody to DENV. The definition of the parameter θz is
similar to the definition of θd, while the switching function S(Ad) is of the form in equation (2.3).3. Material and methods
3.1. Data
We obtained data on dengue viral loads from an experimental study on macaques infected by DENV [9],
as shown in figure 3. There are two columns of dengue viral loads in table 1 reflecting the results of the
experimental study [9]. One of these is obtained by testing the macaque infected with DENV only, as
shown in figure 3a, while the other column is obtained by testing the ZIKV convalescence macaque
super-infected with DENV, as shown in figure 3b. Comparing the two columns of dengue viral loads,
we can easily see that the peak viral load of the secondary infection is significantly higher than the
peak viral load of the primary infection.
3.2. Parameter estimation procedure
To calibrate the parameters for the primary infection ofDENV, that is, all the parameter values ofmodel (2.1)
corresponding to DENV infection, we fix the lifespan of target cells and infected cells as 7 days, hence,
μ = δ = 1/7≈ 0.14 [28]. One infected cell can produce 10 000 virus per day, thus, we set ωd = 1 × 104
[28,32]. Referring to the modelling study on the within-host dynamics of ZIKV [32] and the study on the
within-host dynamics of influenza [34], we fix the clearance rate of DENV as 10 (i.e. cd = 10). At the
initial time, we assume that no target cell is infected, thus Id(0) = 0. Furthermore, the initial dengue viral
load is arbitrarily set to 1. Hence, the main task is to estimate the remaining parameters of model (2.1),
including the recruitment rate Λ, the infection rate βd, the production rate of DENV-specific antibody ad,
the neutralization rate of DENV-specific antibody to DENV bd, the decay rate of DENV-specific antibody
σd, the initial value of target cells T(0), and the initial DENV-specific antibody Ad(0).













































Figure 3. Data information from the existing experimental study [9]. (a) Data of dengue viral loads from macaque infected with
DENV only. (b) Data of dengue viral loads from ZIKV convalescence macaque super-infected with DENV. Here, the bars are the mean






































Furthermore, we calibrate the parameters for the secondary infection of DENV with previous
infection of ZIKV (i.e. the parameters of model (2.2)), in particular, estimating the parameters
corresponding to the cross-immune response. To do this, the parameters related to DENV-infection
and DENV-specific immune response are treated in the same manner as those in the primary infection
of DENV, that is, all the parameters in model (2.1). This includes Λ, μ, δ, βd, ωd, ad, bd, cd, σd. Similarly,
we fix the initial values of the infected cells as 0 and assume that the initial dengue viral load is 1. We
assume that the initial target cell and the initial DENV-specific antibody are of the same values
estimated by model (2.1). Therefore, we only need to estimate the production rate of ZIKV-specific
antibody owing to cross-immune response κ, the clearance rate of ZIKV-specific antibody σsz, the
maximum changing rate of free DENV owing to the cross-reactive response of ZIKV-specific antibody
θd, the parameters of the switching function Amin and Amax, and the initial ZIKV-specific antibody Az(0).
We use the Markov chain Monte Carlo (MCMC) method to fit the model, and adopt an adaptive
Metropolis–Hastings algorithm to carry out the MCMC procedure [37]. The algorithm is run for 800
000 iterations with a burn-in of the first 400 000 iterations, and the Geweke convergence diagnostic
method is employed to assess convergence of chains. More specifically, using the MCMC method, we
fit model (2.1) to the data of dengue viral load from macaque infected with DENV only, as shown
figure 4a. We then estimate the unknown parameter values of model (2.1) and their standard
deviations, as listed in table 1. We next fit model (2.2) to the data of dengue viral load from ZIKV
convalescence macaque super-infected with DENV, estimate the cross-immune response related
parameter values (κ, σsz, θd, Amin, Amax), the initial ZIKV-specific antibody (Az(0)), and their standard
deviations, which are listed in table 1 as well.
In addition, we use the coefficient of determination (R2) measure to estimate the goodness of fit for
our model fitting results. Given an observed data y (in the n-dimensional Euclidean space) and the
corresponding estimated values from the model ŷ, the coefficient of determination (R2) value can be
calculated as
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Figure 4. Results of model fitting. (a) Fitting model (2.1) to the dengue viral loads from macaque infected with DENV only. (b) Fitting
model (2.2) to the dengue viral loads from ZIKV convalescence macaque super-infected with DENV. The blue circles represent the mean






































where SSerr and SStot are the sum of squares of residuals (residual sum of squares) and the total sum of








with y ¼ 1n
Pn
i¼1 yi. Therefore, based on formula (3.1), we can obtain that the coefficients of determination
for the model fitting results in figure 4a and figure 4b are 0.92 and 0.9, respectively.3.3. Sensitivity analysis
SA is a method to identify critical inputs (parameters and initial conditions) of a model and quantify how
input uncertainty impacts model outcomes [38]. Among the alternative sampling-based methods for
performing SA, partial rank correlation coefficient (PRCC), as a global technique, is one of the most
efficient and reliable methods. Usually, the PRCC method is combined with the Latin hypercube
sampling (LHS) method, which requires fewer samples than simple random sampling to achieve the
same accuracy [39]. Therefore, we use the standard PRCC-LHS scheme to perform the SA, and then
identify the key parameters contributing to the augmentation of the peak viral load and peak time in
the primary infection and the secondary infection. Here, we explored the parameter space by
performing an uncertainty analysis using the LHS method, and chose a normal distribution for all the
input parameters with mean value and standard deviation in the absence of available data on the
distribution functions. Furthermore, we use the t-test to perform the significance test to check if a
PRCC is significantly different from zero.4. Main results
Our estimations show that, owing to the pre-existing immunity to ZIKV, in the secondary DENV
infection, the cross-immune response of ZIKV-specific antibody to DENV is built up faster and higher
than the DENV-specific immune response with Az(0) >Ad(0) and κ > ad. Similarly, in figure 5, it is
shown that in the secondary DENV infection, the concentration of ZIKV-specific antibody is always
higher than the DENV-specific antibody during the infectious period, which is in line with the
experimental study [9]. Comparing the best fitting curves in figure 4a and b, we note that the peak
viral load of the secondary infection is much higher than the peak viral load of the primary infection
owing to the high level cross-immune response. Moreover, we observe that the peak of the primary
infection is much more gradual than the peak of the secondary infection, while a sharp increase of the
dengue viral load before the peak time and a sharp decrease after the peak time occurs (figure 4b),
which is also consistent with the experimental observations in the study [9].
days post-infection









Figure 5. The curves of the concentrations of DENV-specific antibody and ZIKV-specific antibody by solving model (2.2). All the




































Figure 6. Solutions of model (2.2) with and without ADN. Red curve: the fitting curve of model (2.2). Blue curves: dengue viral
loads by solving model (2.2) while we set S(Az) = 0 when Az > Amax in contrast to the red curve. All the parameter values are fixed






































In order to examine the key factors determining the sharp peak in the secondary infection, we set
S(Az) = 0 when Az >Amax (i.e. ignore the cross-neutralization of ZIKV-specific antibody to DENV) and
plot the dengue viral loads in figure 6. It follows from figure 6 that ADN has little impact on the
sharp peak viral load, while it can only help in clearing the DENV in the last stage of the infectious
period. This indicates that ADE is the main factor contributing to the sharp increase and sharp
decrease of the viral loads in the secondary infection.
In figure 7, we use a PRCC to conduct the SA of the peak dengue viral load and the peak time to all
the estimated parameters. It follows from figure 7a that in the primary infection of DENV, there are four
PRCC values that are significantly different from zero, including the infection rate βd, the production rate
of DENV-specific antibody ad, the neutralization rate bd, and the recruitment rate of target cell Λ. βd is
ranked the first that is positively correlated to the peak dengue viral load among these examined
parameters, while βd is the first parameter with negative impact on the peak time. This means that
increasing the value of βd can greatly increase the peak dengue viral load with an earlier peak time.
However, in the secondary DENV infection, the infection rate βd is of a very small PRCC value related
to the peak virus load, as shown in figure 7b. Instead, θd and Amax become the first two parameters




























significant (p < 0.01)
(a)
(b)
Figure 7. Sensitivity analysis. (a) PRCCs of the peak dengue viral load and the peak time for the primary DENV-infection (i.e. model
(2.1)); (b) PRCCs of peak dengue viral load and the peak time for the secondary DENV-infection with a previous ZIKV-infection (i.e.






































that are positively correlated to the peak viral load. This means that the high-level ADE effect and the
delayed ADN effect of ZIKV-specific antibody to DENV are the key factors contributing to the much
higher peak viral load in the secondary infection. We further noticed that the infection rate βd remains
the first parameter highly correlated to the peak time in the secondary infection, i.e. the larger βd, the
earlier the peak time. According to figure 7b, the parameters θd and Amax have a similar impact on the
peak time.
Next, we consider the impact of ADE on the virus dynamics of both DENV and ZIKV when an
individual is coinfected with the two viruses. Two kinds of co-infection are considered here, i.e.
simultaneous co-infection or subsequent co-infection. We initially assume that one individual is
infected with DENV and ZIKV simultaneously. Based on the parameter estimations of model (2.1), we
set the initial condition as (1.98 × 106, 0, 0, 1, 1, 0.988, 0.988) for model (2.4). Then, by changing the
values of the parameters θd and θz and fixing all the other parameter values, we plot the dengue viral
loads and the Zika viral loads in figure 8. Comparing figure 8 to figure 4a, we find that as for the
simultaneous co-infection, the ADE effect has very limited impact on the virus dynamics of both
DENV and ZIKV. That is, compared with the primary infection of a single virus, the ADE can lead to
only a small increment of the peak viral load for the simultaneous co-infection. This indicates that the
pre-existing immunity of one virus is the key determinant of the high-level ADE effect, consequently,
resulting in the significant increase of the peak viral load of the other virus. This further indicates that
for the subsequent co-infection, ADE may have a great influence on the virus dynamics of the
subsequently-infected virus owing to the pre-existence of immunity to the initially-infected virus.
We further consider the impact of ADE on the virus dynamics of the subsequent co-infection.
Without loss of generality, we assume that individuals are initially infected with ZIKV, and
subsequently infected with DENV. That is, we assume that there is a time delay between the two
infections, hereafter we call the interval of the delay as ‘inter-infections interval (IFI)’. In figure 9, we
set the IFI as 1 day and 5 days, respectively, and plot the dengue viral loads and Zika viral loads. We
treat the initial ZIKV-infection as the primary infection, hence the Zika viral loads during the period
of IFI (the grey curves in figure 9a,c) can be obtained by solving model (2.1) with the initial condition
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Figure 9. Dengue viral loads and Zika viral loads in the case of subsequent co-infection. Here, we set θd = θz = 0 in (a,b) and

























qd = qz = 0
qd =qz = 0.343
qd = qz = 0.6
days post-infection
























qd = qz = 0
qd = qz = 0.343








Figure 8. Solutions of model (2.4) in the case of simultaneous co-infection of DENV and ZIKV with different values of θd and θz.
(a) Dengue viral loads; (b) Zika viral loads. All the other parameter values are chosen from table 1. The small maps on the bottom






































and Ad(0) = 0.988. Therefore, for t > 0, the co-infection model (2.4) can be used to solve both the dengue
viral loads and Zika viral loads (figure 9). Note that, in figure 9a and b, we set θd = θz = 0, that is, we
ignore the cross-reactive response of the antibodies to the viruses. Consequently, the peak of the
second virus (i.e. DENV) decreases (with a later peak time) as the IFI increases, as shown in figure 9b.




































virus in the absence of cross-reactive response between them, as shown in figure 9a. Under the same
parameter setting of figure 9a,b, but including the cross-reactive response of the antibodies to the
viruses by letting θd = θz = 0.45, figure 9c shows that the viral loads of ZIKV can have a second peak
time owing to the ADE effect of DENV-specific antibody to ZIKV. Moreover, the ADE of the initial
virus (ZIKV)-specific antibody to the second virus (DENV) can result in a very large peak viral load
of the second virus with a much earlier peak time, as shown in figure 9d.lishing.org/journal/rsos
R.Soc.Open
Sci.7:1917495. Discussion
In this study, we developed and examined a within-host mathematical model of secondary DENV
infection with a primary infection of ZIKV, and a within-host mathematical model describing the
virus dynamics for the co-infection of DENV and ZIKV. In our setting, we included the antibodies to
describe the humoral immune response, and to parameterize the dynamical cross-immune response
between DENV and ZIKV (i.e. the ADE and the ADN). This seems, to the best of our knowledge, the
first attempt to provide a quantitative framework for understanding the impact of ADE and ADN
effect between DENV and ZIKV on the virus dynamics of both viruses in general, and on the onset of
severe disease by peak viral loads in particular.
By fitting the model to the data of dengue viral loads from the macaque infected with dengue only,
we first calibrated the model parameters relevant to the primary dengue infection. Fixing the parameters
corresponding to the primary dengue infection, we then fitted the model to the data of dengue viral loads
from ZIKV convalescence macaque super-infected with DENV, and estimated the parameters related to
cross-reactive response of ZIKV-specific antibody to DENV. From these estimated parameter values, we
found that, owing to the pre-existence of immunity to ZIKV, the cross-immune response of ZIKV-specific
antibody in the secondary DENV infection is much higher and is built-up much faster than the DENV-
specific immune response, in line with the experimental study [9].
Tomodel the impact of ADE, the existing studies [26,27] formodelling secondaryDENV infectionwith a
previous infection of another dengue serotype simply assumed that the humoral immune response stays at
a constant level by re-parameterizing the infection rate to a larger value compared with the primary
infection. This practice may oversimplify the contribution of antibodies to disease severity. By contrast,
our models involved the antibodies to describe the humoral immune response, which can explicitly
describe the dynamical antibody density-dependent cross-immune response between DENV and ZIKV.
The data fitting results in figure 4 show that the primary DENV infection is characterized by a more
gradual peak in viraemia while the secondary DENV infection has a very sharp peak in viraemia, also
consistent with the study [9]. In other words, the secondary DENV infection with a primary ZIKV
infection is of shorter duration than the primary dengue infection. In order to identify the key factors
determining the sharp peak in the secondary infection, we plotted the viral loads in figure 6 by ignoring
the ADN effect, and we concluded that ADN has very small impact on the sharp peak, including the
sharp increase and the sharp decrease. This shows that ADE is the main factor determining the sharp
increase/decrease of the viral loads around the peak time in the secondary infection.
To identify the key parameter of ADE contributing to the significant increment of the peak viral load
in detail, we conducted an SA. The analysis shows that the infection rate βd is the most significant
parameter with the largest PRCC value for the peak viral load in the primary infection while it has a
very small PRCC value in the secondary infection. Instead, the parameters related to the cross-reactive
response of ZIKV-specific antibody to DENV θd, Amax emerge as the parameters that are highly
correlated to the peak viral load with great PRCC values. We, therefore, predict that the ADE of ZIKV
to DENV can significantly increase the peak viral load in the secondary DENV infection. We also
identified the infection rate βd as the most significant parameter negatively correlated to the peak time
in both the primary infection and the secondary infection. Therefore, increasing the value of βd can
significantly move the peak time ahead.
Through numerical simulations, we quantitatively examined the impact of ADE on the virus
dynamics of both DENV and ZIKV when an individual is coinfected with the two viruses. In the
current study, we considered two types of co-infection, i.e. simultaneous co-infection and subsequent
co-infection. As for the case of simultaneous co-infection, we predict that the increment of the peak
viral load induced by ADE is very small compared with sharp increase in the secondary infection.
This means that the pre-existence of immunity to one virus is the determinant of the high-level ADE
effect, which also indicates that the ADE effect may have a greater influence on the second virus






































Furthermore, we assumed that an individual was firstly infected with ZIKV and subsequently infected
with DENVwith a delay by a magnitude of several days, called the IFI between the two viruses. We found
that in the absence of ADE between the two viruses, as the IFI increases, the peak viral load of the second
virus decreases with a later peak time. Meanwhile, we found that there is little impact on the initial virus
without ADE effect. This leads to the observation that subsequent co-infection is less damaging to the host
compared with the simultaneous co-infection in the absence of ADE. However, if we include ADE, our
simulations predict that the subsequent co-infection can result in a significant increment of the peak
viral load of the second virus (DENV) with an earlier peak time. Moreover, owing to ADE, there can be
a prolonged time period of the high level of viral loads or a second peak viral load for the initial virus
(ZIKV). Therefore, we predict that owing to the ADE effect, the subsequent co-infection is more
damaging to the host compared with the simultaneous co-infection.
It should be mentioned that the simplifying assumptions of our mathematical models result in a
number of limitations. In the current study, we only included the immune response induced by
antibodies. In reality, the immune response should be much more complex, and multiple immune
cells, such as the T-cells and natural killer cells can play important roles in virus clearance [40]. We
examined and predicted the impact of ADE on the viral dynamics of both DENV and ZIKV in the
case of co-infection, however, the parameters of our co-infection model (i.e. model (2.4)) were not
inferred from fitting experimental or clinical co-infection data. Instead, we used parameters inferred
from fitting the data in the primary and secondary infection of DENV only. The study will benefit
from future co-infection experiments. Despite these limitations, we believe that our study provides a
solid qualitative framework for understanding the impact of the ADE effect between DENV and ZIKV
on their virus dynamics, and hence, on the onset of severe disease.
In summary, we examined the impact of ADE and ADN effect between DENV and ZIKV on the onset
of severe disease by peak viral load using mathematical models. We calibrated the model using the
available data and our analyses are qualitatively in agreement with the experimental study, that the
peak viral loads of the primary DENV infection is much more gradual compared with the secondary
DENV infection with a primary ZIKV infection. Our numerical simulations predict that pre-existing
immunity to ZIKV is the determinant of a high level of ADE effect to the secondary infection or the
subsequent co-infection of DENV. Owing to the ADE effect, a subsequent co-infection can induce
greater damage to the host with a higher peak viral load and a much earlier peak time for the second
virus.
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